Clinical outcomes and safety in patients with lower‐risk myelodysplastic syndromes treated with imetelstat: Substudy of the phase 3 IMerge trial
Year: 2025
Type: article
Source: British Journal of Haematology
DOI: 10.1111/bjh.70266
Authors: Rami S. Komrokji, Valeria Santini, Uwe Platzbecker, Koen Van Eygen, María Díez‐Campelo, Raquel de Paz, Guillermo Sanz Santillana, Sylvain Thépot, Maciej Kaźmierczak, Esther Natalie Oliva, Mikkael A. Sekeres, Pierre Fenaux, Yazan F. Madanat, Michael R. Savona, Jennifer Riggs, Sheetal Shah, Ashley L. Lennox, Qi Xia, Libo Sun, Tymara Berry, Amer M. Zeidan
Institutions: Moffitt Cancer Center, Azienda Ospedaliero-Universitaria Careggi, University of Florence, University Hospital Carl Gustav Carus, Nationales Centrum für Tumorerkrankungen Dresden, Technische Universität Dresden, AZ Groeninge, Universidad de Salamanca, Instituto de Investigación Biomédica de Salamanca, Hospital Universitario La Paz, Instituto de Salud Carlos III, Hospital Universitari i Politècnic La Fe, Centro de Investigación Biomédica en Red de Cáncer, Instituto de Investigación Sanitaria La Fe, Centre Hospitalier Universitaire d'Angers, Poznan University of Medical Sciences, London North West Healthcare NHS Trust, University of Miami, Sylvester Comprehensive Cancer Center, Hôpital Saint-Louis, Université Paris Diderot, Harold C. Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Geron (United States), Yale Cancer Center, Yale University
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,190
OpenAlex ID: W4416837404